You are here

CELDARA MEDICAL, LLC

Company Information
Address
16 CAVENDISH CT
LEBANON, NH 03766-1441
United States


http://www.celdaramedical.com

Information

UEI: MMVKQXZUBMQ7

# of Employees: 15


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR Success: Celdara Medical LLC

    How much good could you do with $30 billion dollars and the smartest people in the world? That is the question that the founders of Celdara Medical asked themselves when beginning the company in 2008.Each year, the National Institutes of Health allocates $30 billion to the best and brightest...

Award Charts




Award Listing

  1. Gene Expression Signatures to Predict Treatment Response in Systemic Sclerosis

    Amount: $1,494,019.00

    DESCRIPTION provided by applicant Today systemic sclerosis SSc clinical trials generally include all subsets some may benefit others do not confounding measures of efficacy Because each expr ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  2. Combination immunotherapies for the treatment of melanoma

    Amount: $288,300.00

    DESCRIPTION (provided by applicant): Melanoma is the most common form of cancer in young adults1, and its incidence is rising at a rate higher than any of the seven most common cancers2, increasing 45 ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  3. Depletion of Dendritic Cells by Immunotoxin as Therapy for Myocardial Infarction

    Amount: $2,068,342.00

    DESCRIPTION (provided by applicant): MI is the leading cause of death in the developed world, including the United States. In 2005 over 8.1 million Americans had an MI; 30% died before reaching hospit ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  4. ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial

    Amount: $3,219,451.00

    DESCRIPTION (provided by applicant): The global burden of cancer doubled between 1975 and 2000. Cancer became the leading cause of death worldwide in 2010, and is projected to double again by 2020 an ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  5. Preclinical Development of a Novel Plaque-Regressing Therapy For Atherosclerosis

    Amount: $675,944.00

    DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is the leading cause of death in the world. The staggering mortality rate is expected to increase significantly in the next ten years ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  6. Scleroderma Subtyping from Fresh and Archived Biopsies using NextGen Sequencing

    Amount: $535,368.00

    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is an autoimmune disease that presents with a heterogeneous and complex phenotype. Major manifestations of the disease are skin fibrosis, ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  7. Development of a Novel Anti-Inflammatory Therapeutic Based on Antithrombin

    Amount: $747,897.00

    DESCRIPTION (provided by applicant): Septic shock is a dire outcome of sepsis, an acute systemic inflammatory state triggered by an infection. In the USA, over 750,000 episodes of sepsis occur each ye ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  8. TCR-less Targeted T Cells Against Cancer

    Amount: $391,529.00

    DESCRIPTION (provided by applicant): This year cancer will become the leading cause of death worldwide. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected to double ag ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  9. ChNKG2D-Targeted Cellular Cancer Therapy: Preclinical Toxicology

    Amount: $413,428.00

    DESCRIPTION (provided by applicant): Cancer is projected to become the leading cause of death worldwide by 2010. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected t ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  10. Myocardial Infarction Therapeutics

    Amount: $199,085.00

    DESCRIPTION (provided by applicant): Myocardial infarction (MI) is the leading cause of death in the developed world, including the United States. Each year over 8.1 million Americans have an MI; 30% ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government